Please assess the completion status of the following clinical trial:

Trial Title: Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~* Able to provide written informed consent~* Healthy male or female between 18 to 45 years of age, inclusive at the time of screening~* Additional inclusion criteria apply~Part B:~* 18 - 55 years old inclusive at Screening~* Active but clinically stable, plaque psoriasis~* Psoriasis involving ≥ 10% of the body surface area~* A minimum PASI score of ≥ 10 obtained during the screening period~* Additional inclusion criteria apply~Exclusion Criteria:~Part A:~* History or evidence of a clinically significant disorder (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric), condition or disease that, in the opinion of the Investigator and Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures or completion~* Underlying condition that predisposes the subject to infections (eg, uncontrolled diabetes - HbA1c \> 7%, history of splenectomy)~* Additional exclusion criteria apply~Part B:~* Active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit~* Evidence of skin conditions other than psoriasis (eg, eczema) at the time of the screening visit or between the screening visit and study drug initiation that would interfere with evaluations of the effect of investigational product on psoriasis~* Any condition that, in the judgment of the investigator, might cause this study to be detrimental to the subject~* Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo treatment
- 140 mg SC (Type: EXPERIMENTAL): 140 mg SC PsO
- 350 mg SC (Type: ACTIVE_COMPARATOR): 350 mg SC PsO
- 700 mg IV (Type: EXPERIMENTAL): 700 mg IV PsO

Based on this trial design, predict the completion outcome and termination type (if applicable).